China National Accord Medicines sees mixed H1 2025 results amid revenue dip

In the first half of 2025, China National Accord Medicines Corporation reported a 2.62% decrease in total operating revenue to 36.79 bn yuan and a 10.43% decline in net profit attributable to shareholders, reaching 665.9m yuan. Despite these downturns, the company's financial health remained stable, with total assets increasing by 6.04% to 50.43 bn yuan.

The company's retail pharmacy business, National Accord Drugstore, saw a 215.81% increase in net profit, driven by optimized procurement, private-label growth, and strategic store closures, including 863 unprofitable locations. Cash flow from financing activities surged by 36.68%, reaching a net inflow of 662.8m yuan, attributed to increased bank borrowings and reduced dividend payments to shareholders.

Concurrently, National Accord Medicines approved an external donation budget of 130,000 yuan for 2025. The company's internal control and risk management systems for financial operations were deemed sound and effective, with no major deficiencies found in the first half of 2025.